HRP20231448T1 - Primjena delgocitiniba za liječenje kroničnog ekcema ruku - Google Patents

Primjena delgocitiniba za liječenje kroničnog ekcema ruku Download PDF

Info

Publication number
HRP20231448T1
HRP20231448T1 HRP20231448TT HRP20231448T HRP20231448T1 HR P20231448 T1 HRP20231448 T1 HR P20231448T1 HR P20231448T T HRP20231448T T HR P20231448TT HR P20231448 T HRP20231448 T HR P20231448T HR P20231448 T1 HRP20231448 T1 HR P20231448T1
Authority
HR
Croatia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
treatment
Prior art date
Application number
HRP20231448TT
Other languages
English (en)
Croatian (hr)
Inventor
Tero WENNBERG
Anders Per SØRENSEN
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55236207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20231448(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of HRP20231448T1 publication Critical patent/HRP20231448T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
HRP20231448TT 2016-01-21 2017-01-20 Primjena delgocitiniba za liječenje kroničnog ekcema ruku HRP20231448T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16152215 2016-01-21
EP17701828.0A EP3405197B1 (en) 2016-01-21 2017-01-20 Use of delgocitinib for the treatment of chronic hand eczema
PCT/EP2017/051133 WO2017125523A1 (en) 2016-01-21 2017-01-20 Treatment of hand eczema

Publications (1)

Publication Number Publication Date
HRP20231448T1 true HRP20231448T1 (hr) 2024-03-01

Family

ID=55236207

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231448TT HRP20231448T1 (hr) 2016-01-21 2017-01-20 Primjena delgocitiniba za liječenje kroničnog ekcema ruku

Country Status (31)

Country Link
US (3) US20200397787A1 (cg-RX-API-DMAC10.html)
EP (2) EP4257205A3 (cg-RX-API-DMAC10.html)
JP (1) JP6929860B2 (cg-RX-API-DMAC10.html)
KR (2) KR20180102662A (cg-RX-API-DMAC10.html)
CN (3) CN117159553A (cg-RX-API-DMAC10.html)
AU (3) AU2017209932A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018014769A2 (cg-RX-API-DMAC10.html)
CA (1) CA3010547A1 (cg-RX-API-DMAC10.html)
CY (2) CY1126388T1 (cg-RX-API-DMAC10.html)
DK (1) DK3405197T3 (cg-RX-API-DMAC10.html)
ES (1) ES2963784T3 (cg-RX-API-DMAC10.html)
FI (2) FI3405197T3 (cg-RX-API-DMAC10.html)
FR (1) FR24C1053I2 (cg-RX-API-DMAC10.html)
HR (1) HRP20231448T1 (cg-RX-API-DMAC10.html)
HU (2) HUE064192T2 (cg-RX-API-DMAC10.html)
IL (4) IL320757A (cg-RX-API-DMAC10.html)
LT (2) LT3405197T (cg-RX-API-DMAC10.html)
MX (2) MX394358B (cg-RX-API-DMAC10.html)
NL (1) NL301306I2 (cg-RX-API-DMAC10.html)
NO (1) NO2024058I1 (cg-RX-API-DMAC10.html)
PL (1) PL3405197T3 (cg-RX-API-DMAC10.html)
PT (1) PT3405197T (cg-RX-API-DMAC10.html)
RS (1) RS64798B1 (cg-RX-API-DMAC10.html)
RU (1) RU2018130097A (cg-RX-API-DMAC10.html)
SG (2) SG10202006830WA (cg-RX-API-DMAC10.html)
SI (1) SI3405197T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300415T1 (cg-RX-API-DMAC10.html)
TW (2) TWI783921B (cg-RX-API-DMAC10.html)
UA (1) UA123780C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017125523A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201804098B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3968997T3 (fi) * 2019-05-15 2026-06-09 Leo Pharma As Delgositinibin formulaatio voiteen muodossa
CA3210150A1 (en) * 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
KR20240027044A (ko) * 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료
JP2026509302A (ja) 2023-03-17 2026-03-17 レオ ファーマ アクティーゼルスカブ 中等症ないし重症の慢性手湿疹を有する患者における慢性手湿疹を処置する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20130302298A1 (en) * 2010-11-30 2013-11-14 Bio-K Plus International Inc. Treatment and prevention of eczema
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent

Also Published As

Publication number Publication date
FR24C1053I1 (fr) 2025-02-21
WO2017125523A1 (en) 2017-07-27
SG11201805394QA (en) 2018-08-30
TW201736382A (zh) 2017-10-16
RU2018130097A (ru) 2020-02-21
CN117159554A (zh) 2023-12-05
JP2019502734A (ja) 2019-01-31
MX2018008449A (es) 2018-08-09
TWI841027B (zh) 2024-05-01
US20200397787A1 (en) 2020-12-24
HUS2400045I1 (hu) 2025-01-28
US20230138114A1 (en) 2023-05-04
SG10202006830WA (en) 2020-08-28
AU2022252766B2 (en) 2024-08-29
CY2024037I1 (el) 2026-02-25
JP6929860B2 (ja) 2021-09-01
EP3405197A1 (en) 2018-11-28
CN117159553A (zh) 2023-12-05
FIC20240048I1 (fi) 2024-12-19
AU2024266962A1 (en) 2024-12-19
KR20180102662A (ko) 2018-09-17
AU2017209932A1 (en) 2018-07-05
NO2024058I1 (no) 2024-12-13
UA123780C2 (uk) 2021-06-02
ZA201804098B (en) 2024-10-30
HUE064192T2 (hu) 2024-02-28
EP4257205A2 (en) 2023-10-11
NL301306I2 (nl) 2024-12-30
IL260094A (en) 2018-07-31
US20260216193A1 (en) 2026-07-30
LTPA2024538I1 (cg-RX-API-DMAC10.html) 2025-01-10
CN108472297A (zh) 2018-08-31
RU2018130097A3 (cg-RX-API-DMAC10.html) 2020-05-25
TW202332451A (zh) 2023-08-16
EP4257205A3 (en) 2023-12-20
CY1126388T1 (el) 2026-02-25
IL297379A (en) 2022-12-01
NZ743582A (en) 2024-12-20
IL313543A (en) 2024-08-01
LT3405197T (lt) 2023-11-27
CY2024037I2 (el) 2026-02-25
PL3405197T3 (pl) 2024-02-12
EP3405197B1 (en) 2023-09-06
FR24C1053I2 (fr) 2025-12-05
AU2022252766A1 (en) 2022-11-03
IL320757A (en) 2025-07-01
SI3405197T1 (sl) 2024-03-29
CA3010547A1 (en) 2017-07-27
RS64798B1 (sr) 2023-11-30
FI3405197T3 (fi) 2023-11-23
KR20250088666A (ko) 2025-06-17
ES2963784T3 (es) 2024-04-02
BR112018014769A2 (pt) 2018-12-11
TWI783921B (zh) 2022-11-21
PT3405197T (pt) 2023-12-06
SMT202300415T1 (it) 2024-01-10
MX2022005915A (es) 2022-06-27
MX394358B (es) 2025-03-24
DK3405197T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
HRP20210212T1 (hr) Triciklični spoj kao antikancerogeni agensi
SG10201804024VA (en) Formulations of azaindole compounds
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
HRP20171175T1 (hr) Novi triciklički spojevi
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
WO2018042362A9 (en) Muscarinic m1 receptor positive allosteric modulators
FI4406594T3 (fi) Kilpirauhashormonin analogeja
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
ME02910B (me) Spojevi tetrahidropirolotiazina
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
MX388825B (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
HRP20161295T1 (hr) Primjena antitumorskog sredstva
HRP20230935T1 (hr) Postupci za liječenje i profilaksu hiv-a i aids-a
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
BR112015014433A2 (pt) compostos tricíclicos
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
WO2014144407A8 (en) Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
FI3405197T3 (fi) Kroonisen käsi-ihottuman hoito
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола